BioPhorum Regulatory Interaction: helping to open doors

BioPhorum Regulatory Interaction: helping to open doors

To implement any change in the biopharmaceutical manufacturing industry it is important to engage with and collaborate with the regulators.  Set up two years ago, BPOG’s Regulatory Interaction team has been developed to help phorums and workstreams to connect with regulators in the most constructive way.  Over this period they have formed a strong team who have devised the best ways making sure that our teams knock on the right doors at the right time with the right message.  In this article, we will describe how the Regulatory Interaction team works and the benefits it brings to all BPOG members.

The 30 regulatory experts from over 20 biopharmaceutical companies that comprise the team, bring extensive regulatory expertise and a wealth of experience gained from not only their own companies but from their extended networks and their connections to regulators and other industry groups.

Regulatory Interaction has been described as ‘helping with opening doors’ with regulatory authorities/agencies.  But what might this mean in practice?

Is the door already open?

The Regulatory Interaction team is well placed through its networks to understand the key priorities for regulators. Insight and advice is provided on how to make appropriate connections from BPOG activities to current and future priorities for regulators.  Even if a topic may be a priority for regulators, there might be understandable resistance to cross the threshold at an individual company level.  The Regulatory Interaction team, however, provides a forum for sharing experiences and best practices, encouraging transparency and cross-industry alignment.  A good example of this is around new technology where connections have been established with the related teams in the FDA and the MHRA.

Which Door or Doors?

Often industry and regulators are interested and motivated in progressing a particular topic, however, what may not be so obvious is to whom and how to make the right connections. In consultation with the Regulatory Interaction team, workstreams can discuss their goals and determine how best to engage with regulators.  This can be a ‘direct’ contact with a regulatory agency but may need to start in a more ‘indirect’ manner via a number of other doors – for instance, the preparation of a white paper and then presenting this at a conference, hopefully resulting in more direct contact.  Regulatory Interaction has the expertise and networks to counsel on which routes might be effective.  A current example in progress is for BioPhorum to provide a training seminar for the FDA regulatory product reviewers that will include early sharing of current industry thinking and direction, enabling further engagement and alignment.

‘But that door worked before?’

Organizations evolve over time and another role for the Regulatory Interaction team is to keep aware as regulatory organizations change and ensure that they maintain a current understanding of how to access and contact them and share this across BPOG.

Helping us to knock on the right doors?

In thinking about doors, there are a number of ways to attract attention, assuming you know the person you’d like to meet. The Regulatory Interaction team continues to develop its networks so the right contacts can be made in the right way.  A recent example exploring the widely held industry perception that an authority did not really understand a particular process step that was necessary to justify a process change, discovered that in fact, this wasn’t the case.  Discussing it with Regulatory Interaction tested this assumption and it became clear from benchmarked cross-company observations and experiences, that in fact the process technology is well understood by regulators.  The actual problem, in this case, was diagnosed as being about the understanding of supporting scientific rationale.  In this example, industry should have been able to demonstrate they fully understand the science and theory.  The workstream has now adapted their planned engagement approach that has subsequently led to a planned joint session between industry and regulators in this area.

In Conclusion

BioPhorum’sRegulatory Interaction team is now routinely providing the needed regulatory expertise and advice to the BioPhorum phorums and workstreams for both immediate issues and future strategic opportunities. Designed to enable more effective regulatory engagement planning through better interaction preparation (publications, conferences, meetings), the team’s work increases confidence in achieving successful execution.  As plans develop for new  phorums, the Regulatory Interactions team has work to do in ensuring that the thinking is ‘Global’, for example as in the case of emerging markets.

Finally, it’s clear that regulators are also looking to innovate.  If doors are redesigned, for instance sliding doors, the BioPhorum Regulatory Interaction team are proactively positioned to advise on that too.

Contact address

BioPhorum
The Gridiron Building
One Pancras Square
London
N1C 4AG

Newsletter subscribe

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.



© 2019 Biophorum Operations Group · All Rights Reserved

Registered Address: 5 Westbrook Court · 2 Sharrow Vale Road · Sheffield · S11 8YZ

Company Number 06794795 · VAT Number GB298617544

Driving progress in Cell & Gene Therapy

Now with 19 member companies and 183 subject matter experts, the BioPhorum Cell & Gene Therapy (C>) Phorum has made great strides since its formation[...]

Read More
Cell and Gene Therapy Phorum accelerates progress

The BioPhorum Cell & Gene Therapy Phorum has made significant progress since its creation in 2018 – from building networks and sharing knowledge to endorsing[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Sharing ideas on forced degradation

“Forced degradation studies are an important part of the drug lifecycle process as they can inform many aspects of drug development,” said Jennifer Halley, Principal[...]

Read More
The BioPhorum and USP collaborative journey to new standards

BioPhorum and United States Pharmacopeia (USP) share a common direction – to accelerate biopharma innovation, quality and progress through collaboration.

Read More
Perfecting balanced scorecards for CDMOs

Established in March 2017, the Development Group’s Development Outsourcing effort aims to share and build guidance that will help companies make the best decisions and[...]

Read More
How well can you handle SUS changes?  Take our surveys and see

BioPhorum delivery of value from the disposables five-year plan - supplier change notifications for single-use systems

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Why leaders should go to where work is performed to learn about success, failure and risk
Read More
Hi-tech ambitions for Fill Finish

The Fill Finish Phorum has recently embarked on a series of exciting and ambitious initiatives, exploring new technologies and processes to enhance the efficiency and[...]

Read More
Companies poised to follow ARMM recommendations

The Advanced and Rapid Microbial Methods (ARMM) team set out a clear case for modernizing Environmental Monitoring (EM) in grade A settings: in summary bio-fluorescent[...]

Read More
How to achieve the ‘Goldilocks’ amount of environmental monitoring

Regulators require a risk-based approach to environmental monitoring (EM)… but they give no clear definition of what “risk-based” actually means. The aim of the Environmental[...]

Read More
The ‘how to’ guide to implementing Agile in GxP

The publication of the Guidance on the use of Agile in a GxP Environment document in 2017 was well received.It described how the use of[...]

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Supply chain, forecasting and demand planning solutions gain momentum

The relationship between suppliers and manufacturers is one of the most crucial in biopharmaceutical manufacturing. This is especially the case when forecasting and supply planning.[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
BioPhorum and Rx-360 pilot a joint audit model for single-use systems

BioPhorum and Rx-360 have agreed a pilot to validate the use of the Joint Audit Model in the single-use systems supply chain.

Read More
Removing the roadblocks to continuous biomanufacturing

Continuous downstream processing is increasingly seen as a feasible approach for manufacturing biologics. The industry recognises that it offers advantages over batch-based processing by:

Read More
Changing mindsets with a modular approach

Historically, manufacturers have used a ‘waterfall’ approach when designing and building their production facilities, sequentially resolving and specifying all aspects up front and in detail[...]

Read More
How do you bring technology roadmapping to life?

You use it to make change happen and that is exactly what the Phorum’s leaders did after the first edition of the Biomanufacturing Technology Roadmaps[...]

Read More
Slicing years off change implementation

As the first regulatory authority in Latin America to gain full membership of the International Council for Harmonization (ICH), the Brazilian Health Regulatory Agency (Anvisa)[...]

Read More
BioPhorum Regulatory Interaction: helping to open doors

To implement any change in the biopharmaceutical manufacturing industry it is important to engage with and collaborate with the regulators. Set up two years ago,[...]

Read More
A new way to navigate the regulatory maze of medical technology

How do you prefer to face a challenge? Fly solo or work with a team of like-minded experts? The MedTech Phorum is a new collaboration[...]

Read More
Navigating the maze of medical technology regulation: a solo voyage or a team effort?

Medical technology is a global business, generating annual revenues of over $400bn. The sector encompasses a broad range of technologies: from in-vitro diagnostics and diagnostic[...]

Read More

IaaS Cloud webinar recording play back
Read More
New BPIT guidance to align cloud services to regulatory requirements
Read More
Data Integrity and Agile Webinars to support industry response to regulators
Read More
How to validate informatics in CPV programs

The BioPhorum Continued Process Verification (CPV) and Informatics team has published a paper to support a risk-based approach for the validation of informatics systems for[...]

Read More
Continued Process Verification delivering real saving in time and money

More than 50 per cent of biopharma products on the market now have Continued Process Verification (CPV) plans in place.  Thanks to the CPV white[...]

Read More
A roadmap for the implementation of continued process verification

This article provides a roadmap draws on the content of the CPV case study to provide a step-by-step guide in a more accessible form.

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
Digital plant maturity model webinar replay
Read More
Digital Plant Maturity Model workstream to host webinar
Read More
New guidance available on Forecasting and Demand Planning to streamline supply chain performance
Read More
Host cell proteins poster

This poster presented at the BEBPA Conference, San Francisco builds and consolidates the information currently available in the industry for assessing process risk from Host[...]

Read More
Host cell protein risk assessment, an industry approach

Host cell protein (HCP) constitutes a significant class of process-related impurities in biological drugs.

Read More
BEBPA risk assessment workshop
Read More